Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089043 · ClinicalTrials.gov registry record · Phase 2
A Study in Subjects With Neurogenic Orthostatic Hypotension
A Phase 2 study of Neurogenic Orthostatic Hypotension, sponsored by CuraSen Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT07089043: Recruiting Phase 2 study of Neurogenic Orthostatic Hypotension, sponsored by CuraSen Therapeutics.
NCT07089043 is a Phase 2 study of Neurogenic Orthostatic Hypotension that is actively recruiting participants, run by CuraSen Therapeutics. The registered enrollment target is 12 participants, below the 227-participant average among 4 other Neurogenic Orthostatic Hypotension trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07089043, a Phase 2 study of Neurogenic Orthostatic Hypotension, is actively recruiting participants, sponsored by CuraSen Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).
Primary Outcome
Baseline is defined as the pre-dose measurement on Day 1
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CST-3056
Study Locations (4)
Michigan
- CuraSen Investigational Site - Farmington Hills
New Jersey
- CuraSen Investigational Site - Eatontown
New York
- CuraSen Investigational Site - New York
Tennessee
- CuraSen Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What NCT07089043 shows while recruiting
NCT07089043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 227-participant average among 4 other Neurogenic Orthostatic Hypotension trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neurogenic Orthostatic Hypotension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07089043 reports a single indexed study location in Michigan, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT07089043 about?
NCT07089043 is a clinical study titled "A Study in Subjects With Neurogenic Orthostatic Hypotension". This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).
What is the current status of trial NCT07089043?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2025-09-12. Estimated completion is 2026-03-31.
What conditions does trial NCT07089043 study?
This clinical trial studies the following conditions: Neurogenic Orthostatic Hypotension.
What interventions are being tested in trial NCT07089043?
The interventions under investigation include: Placebo (DRUG), CST-3056 (DRUG).
Who is sponsoring clinical trial NCT07089043?
This trial is sponsored by CuraSen Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089043 being conducted?
This trial has 4 study locations across Michigan, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Orthostatic Hypotension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
-
Natural History Study of Synucleinopathies
RECRUITING
-
CPAP for the Treatment of Supine Hypertension
RECRUITING · NA
-
Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI